Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time